Davy James

1 week ago | appliedclinicaltrialsonline.com | Davy James

Elinzanetant Significantly Reduces Vasomotor Symptoms. Patients receiving elinzanetant experienced a statistically significant reduction in moderate-to-severe vasomotor symptoms at both four and 12 weeks compared to placebo, with over 70% achieving at least a 50% symptom reduction. Improved Sleep and Quality of Life with Elinzanetant.

1 week ago | appliedclinicaltrialsonline.com | Davy James

Breyanzi Achieves High Overall Response Rate in R/R MZL. In the Phase II TRANSCEND FL trial, Breyanzi demonstrated a 95.5% overall response rate and a 62.1% complete response rate in patients with relapsed or refractory marginal zone lymphoma (MZL). Durable Efficacy Observed in Long-Term Follow-Up. At median follow-ups nearing two years, Breyanzi showed an 88.6% duration of response, 85.7% progression-free survival, and 90.4% overall survival in the MZL cohort.

2 weeks ago | appliedclinicaltrialsonline.com | Davy James

Sotyktu Meets Primary Endpoint in POETYK PsA-1 Trial. In the Phase III POETYK PsA-1 trial, 54.2% of patients receiving Sotyktu achieved an ACR20 response at week 16 compared to 34.1% on placebo (p<0.0001), demonstrating significant efficacy in reducing PsA symptoms. Broad Improvements Across Key Secondary Endpoints.

2 weeks ago | appliedclinicaltrialsonline.com | Davy James

Tremfya Reduces Structural Joint Damage in PsA. Phase IIIb APEX trial results show that guselkumab significantly inhibited radiographic progression of joint damage at 24 weeks in patients with active psoriatic arthritis, as measured by the modified van der Heijde-Sharp (vdH-S) score. Improved Joint and Skin Symptoms Observed.

2 weeks ago | appliedclinicaltrialsonline.com | Davy James

Imdelltra Outperforms Chemotherapy in SCLC. In the Phase III DeLLphi-304 trial, Imdelltra (tarlatamab) significantly improved overall survival (13.6 months vs. 8.3 months) and progression-free survival in patients with relapsed small-cell lung cancer (SCLC) compared to standard chemotherapy options. Improved Symptom Control and Safety Profile. Patients treated with Imdelltra experienced greater relief from common SCLC symptoms such as dyspnea and cough, and had fewer grade ≥3 adverse events (54% vs.